Novo Nordisk raised its full-year outlook following a strong second-quarter report, primarily driven by rising demand for its Wegovy weight loss pill. This announcement, made on Tuesday, underscores the company’s robust performance amid increasing competition in the market.
In the second quarter, the Danish pharmaceutical company’s adjusted operating profit reached 33.4 billion Danish kroner, equivalent to approximately $5.15 billion. This figure marks an 11% increase on a constant-exchange-rate basis. Additionally, net sales were reported at 78.5 billion kroner, reflecting a 3% rise under similar conditions. These results surpassed industry analysts’ expectations, who had forecasted an operating profit of around 28.74 billion kroner.
As a result of this performance, Novo Nordisk now anticipates that its adjusted sales and operating profit for the entirety of 2026 will show less decline than previously expected. The company revised its guidance to a range between zero and minus 6%, an improvement from the earlier estimates of minus 12% to minus 4%.
The Wegovy pill, introduced to the U.S. market, has now generated over 5 million prescriptions since its launch. Recently, weekly prescriptions totaled more than 265,000 and the medication has also launched in the United Arab Emirates and the United Kingdom, with further expansion planned in additional markets.
Amidst this success, Novo Nordisk faces considerable competition from U.S. rival Eli Lilly, which currently dominates the injectable weight loss segment. Novo Nordisk has initiated legal action against Eli Lilly, alleging misleading marketing practices to which Lilly has responded with denial. An earnings call is scheduled for Wednesday at 7:00 am Eastern time, during which further details may emerge.
Test Your Understanding
How much do you know?
